Abstract |
Recent clinical data suggest that fluconazole at daily doses of 200 to 400 mg for at least 6 months is moderately effective therapy for non-life-threatening blastomycosis. To examine the usefulness of higher doses of fluconazole therapy for this disorder, we conducted a multicenter, randomized, open-label study to determine the efficacy and safety of two different daily doses of fluconazole (400 and 800 mg) in the treatment of non-life-threatening blastomycosis. Of 39 patients evaluable for efficacy analysis, 34 (87%) were successfully treated, including 89% and 85% of patients who received 400 and 800 mg, respectively. Five (83%) of six patients for whom prior antifungal therapy had failed were successfully treated. The mean duration of therapy was 8.9 months for successfully treated patients. Nineteen patients (48%) reported adverse events, although most were minor. We conclude that fluconazole at daily doses of 400 to 800 mg for at least 6 months is effective therapy for non-life-threatening blastomycosis.
|
Authors | P G Pappas, R W Bradsher, C A Kauffman, G A Cloud, C J Thomas, G D Campbell Jr, S W Chapman, C Newman, W E Dismukes |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 25
Issue 2
Pg. 200-5
(Aug 1997)
ISSN: 1058-4838 [Print] United States |
PMID | 9332510
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antifungal Agents
- Fluconazole
|
Topics |
- Adolescent
- Adult
- Aged
- Antifungal Agents
(administration & dosage, adverse effects, therapeutic use)
- Blastomycosis
(drug therapy)
- Female
- Fluconazole
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Male
- Middle Aged
- Treatment Failure
- Treatment Outcome
|